IMRT vs Proton Therapy in Esophageal Cancer

Video

This video reviews the advantages and disadvantages of IMRT and proton therapy for the treatment of esophageal cancer.

The current standard for treating patients with esophageal cancer is 3D radiation, but newer technologies such as intensity-modulated radiation therapy (IMRT) and proton therapy have shown the ability to reduce toxicity by limiting radiation to the surrounding tissue.

In this video, Steven H. Lin, MD, PhD, of the University of Texas MD Anderson Cancer Center, reviews IMRT and proton therapy, discussing some of the advantages and disadvantages.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Related Content
Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.

Bemarituzumab Regimen Improves Survival in FGFR2b+ Gastric/GEJ Cancer

Russ Conroy
July 3rd 2025
Article

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Exercise-Based Regimen Shows Efficacy Promise in CRC

Exercise-Based Regimen Shows Efficacy Promise in CRC

Ariana Pelosci
June 30th 2025
Article

Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO Annual Meeting.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Certepetide Displays Positive Efficacy Trend in Metastatic PDAC

Roman Fabbricatore
June 27th 2025
Article

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.

Elraglusib Plus Chemo Improves OS in Metastatic PDAC With Liver Metastases

Tim Cortese
June 27th 2025
Article

Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.